NRx shares jump 39% on new clinical data testing its experimental COVID-19 drug in the critically ill
Marketwatch -

Shares of NRx Pharmaceuticals Inc. soared 39.9% in premarket trading on Thursday after the company said new peer-reviewed data published in the Journal of Infectious Diseases and Treatment showed that its experimental COVID-19 therapy improved survival in critically ill patients. The data came from an open-label trial assessing respiratory failure in 21 patients who were too sick to participate in the company's Phase 2b/3 trial evaluating the drug, aviptadil, in COVID-19 patients with...

Read this story at

Loading...

Related Articles